Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.5% | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -296.9% | – | – | -833.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -303.5% | – | – | -718.3% |
| EPS Diluted | -0.26 | -0.41 | -0.42 | -0.38 |
| % Growth | 36.6% | 2.4% | -10.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |